Literature DB >> 194022

Immunobiology of primary intracranial tumors.

M S Mahaley, R E Gentry, D D Bigner.   

Abstract

The avian sarcoma virus-induced glioma model in rats was used to study the effectiveness of immunotherapy, namely, Bacillus Calmette-Guérin (BCG) with or without sarcoma cells and/or chemotherapy with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), upon survival times. The most consistent prolongation of survival time was produced by triple therapy: BCG + intraperitoneally administered sarcoma cells + intravenously administered BCNU.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194022     DOI: 10.3171/jns.1977.47.1.0035

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

Review 1.  Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas.

Authors:  R F Barth
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

Review 2.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

3.  Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report.

Authors:  Y el-Hennawi; G Y Gillespie; M S Mahaley; D D Bigner
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

4.  Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model.

Authors:  M Wiranowska; A A Gonzalvo; S Saporta; O R Gonzalez; L D Prockop
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

5.  Current brain tumour models with particular consideration of the transplantation techniques. Outline of literature and personal preliminary results.

Authors:  B Rama; O Spoerri; M Holzgraefe; H D Mennel
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.